



**RESOLUTION NO. 2017-01  
A RESOLUTION OF THE GOVERNING BOARD  
OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
HONORING C. RANDAL MILLS, Ph.D., FOR HIS SERVICE TO  
THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE,  
STEM CELL RESEARCH, AND CALIFORNIA PATIENTS**

WHEREAS, C. Randal Mills earned his Bachelor degree in microbiology and cell science and a Ph.D. in drug development from the University of Florida;

WHEREAS, Dr. Mills was a founding member of the University of Florida Tissue Bank and served in several executive leadership roles with the Bank's successor entity, RTI Biologics, Inc.;

WHEREAS, Dr. Mills served as President and Chief Executive Officer of Osiris Therapeutics, which under Dr. Mills' leadership, developed the world's first approved stem cell drug, Prochymal, for the treatment of acute graft-vs-host disease in children, a devastating complication of bone marrow transplantation that can be fatal;

WHEREAS, Dr. Mills served as a member of CIRM's Grants Working Group for five years, as a voting member of the National Institutes of Health and AIDS Research Advisory Council, and as vice chairman of the American Association of Tissue Bank's Standards Committee;

WHEREAS, at the request of Chairman Jonathan Thomas, Dr. Mills agreed to be considered as a candidate for the position of President and Chief Executive Officer of CIRM, and was unanimously selected by the Board on April 30, 2014;

WHEREAS, since taking the helm of CIRM, Dr. Mills engaged the CIRM Board, CIRM team members, external stakeholders, and members of the public in an extensive and open strategic planning process and reconsideration of CIRM's processes;

WHEREAS, the outcome of these efforts, known as CIRM 2.0, constituted a dramatic change in the way the agency does business, significantly reducing the amount of time it takes to approve funding for promising stem cell research, standardizing recurrent program offerings to provide predictable opportunities for funding, improving the quality of approved applications, and implementing objective, milestone-based disbursements to accelerate and incentivize progress;



WHEREAS, under CIRM 2.0 and the strategic plan unanimously adopted by the Board, CIRM added 20 high-quality clinical trials to its portfolio, increased the number of projects CIRM funds each year by 33%, reduced the time it takes to fund an award by 82%, accelerated the rate of patient enrollment in CIRM-funded clinical trials nearly three-fold, and increased the number of milestones hit on time from 19% to 79%;

WHEREAS, Dr. Mills has always kept CIRM's focus on the patients we serve, including by celebrating their courage and strength;

WHEREAS, Dr. Mills is a visionary and highly regarded scientific and business leader who is committed to accelerating stem cell therapies to patients with unmet medical needs and who unified the CIRM Board and team to advance this single and clear mission; and

WHEREAS, Dr. Mills, through his experience, commitment, knowledge, and leadership, contributed greatly to the momentum of discovery and the future therapies which will be the ultimate outcome of the dedicated work of the researchers receiving CIRM funding.

BE IT RESOLVED, that the Governing Board of the California Institute for Regenerative Medicine, on behalf of the people of the State of California, wishes to express its deepest gratitude to Dr. C. Randal Mills, for his service to CIRM and for his dedication to accelerating stem cell treatments to patients with unmet medical needs.

This resolution shall take effect immediately upon its approval.

Date Approved: \_\_\_\_\_

Signed: \_\_\_\_\_

Jonathan Y. Thomas  
Chairman, Governing Board  
California Institute for Regenerative Medicine